News News

Sirnaomics News Placeholder 04
June 2, 2017 Sirnaomics Initiates a Clinical Phase IIa Study of Its Leading siRNA Therapeutic Candidate, STP705

Sirnaomics announced today that the company had initiated a Clinical Phase IIa Study for its leading siRNA therapeutic candidate, STP705 (Cotsiranib®), for evaluation of the safety and efficacy of STP705 in human subjects with hypertrophic scar.

May 1, 2017 Sirnaomics Received IND Approval from CFDA for Its Leading siRNA Therapeutic Candidate, STP705

The IND was filed through a chemo-drug category 1.1 application based on CFDA requirement. The approval represents a milestone event for the company and, more importantly, it marks the first in the country allowing innovative siRNA therapeutics to enter clinical study, with the IND filed from a domestic company.

Sirnaomics News Placeholder 02
February 6, 2017 Sirnaomics Initiates a Clinical Phase IIa Study of Its siRNA Drug to Treat Hypertrophic Scar

Sirnaomics announced today that the company had initiated a Clinical Phase IIa Study for its leading siRNA therapeutic candidate, STP705 (Cotsiranib®), for evaluation of the safety and efficacy of STP705 in human subjects with hypertrophic scar.

Sirnaomics News Placeholder 01
November 7, 2016 Sirnaomics Received Green Light from US FDA for a Clinical Phase IIa Study of Its Leading siRNA Drug

Sirnaomics announced today that an IND application for a Phase IIa clinical study of the company’s leading siRNA therapeutic candidate, STP705 (Cotsiranib®) has received approval from U.S. Food and Drug Administration.

Sirnaomics News Placeholder 05
May 4, 2016 Sirnaomics Raises $10M and Forges a Path to Clinical Development of Its Anti-fibrosis RNAi Drug

This follows on previous round of venture capital investment and non-diluted grant funding up to a total amount of US$25 million. This round of financing was led by Hong Kong based venture capital firm, Value Measured Investment Limited.

Sirnaomics News Placeholder 04
January 21, 2016 Sirnaomics Files to Begin Trial of Scar-healing Drug in China

Sirnaomics this month said it has filed to begin Phase I testing of its siRNA-based treatment for hypertrophic skin scars in China, marking its first major step toward becoming a clinical-stage drug developer since it was founded nearly eight years ago.

1 8 9 10 11 12